Post by PHASE Scientific Americas

The FDA just approved a new antibiotic for complicated UTIs—and it highlights a growing challenge in frontline care. Infectious Disease Special Edition (IDSE) reported the approval of cefepime‑zidebactam (Zaynich) for cUTI, including pyelonephritis. It’s designed to address multidrug‑resistant gram‑negative pathogens—a rising concern across healthcare. ⚠️ Why this matters: UTIs are common, but resistance is making treatment decisions more complex. New antibiotics help, but they don’t solve the core issue: clinicians still need clarity on whether symptoms are truly bacterial. 🔬 Diagnostics drive better decisions Accurate UTI testing supports more targeted prescribing and helps preserve the effectiveness of new therapies like Zaynich. Clearer answers upfront mean better stewardship and better outcomes. At PHASE Scientific, we’re committed to improving UTI evaluation with accessible, reliable diagnostic solutions. 👉 Connect with our team: https://lnkd.in/gmuScbKu Source article: https://lnkd.in/gvjNxjuh #UTI #Diagnostics #AntimicrobialResistance #Stewardship #HealthcareInnovation #PHASEScientific

Video Content